Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers
Authors
Keywords
-
Journal
Frontiers in Molecular Biosciences
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-02-28
DOI
10.3389/fmolb.2022.847835
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Exciting New Field of HER2-Low Breast Cancer Treatment
- (2021) Daniel Eiger et al. Cancers
- HER2-/HER3-Targeting Antibody—Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors
- (2021) Kimio Yonesaka Cancers
- Phase I study of the recombinant humanized anti-HER2 monoclonal antibody–MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors
- (2021) Yingying Xu et al. Gastric Cancer
- Addition of Nimotuzumab to Standard TPF Regimen in Locally Advanced Head and Neck Cancer: A Single Institutional Study
- (2021) Samuel Luke Koramati et al. Journal of Oncology
- Amivantamab: First Approval
- (2021) Yahiya Y. Syed DRUGS
- Stepping forward in antibody-drug conjugate development
- (2021) Yiming Jin et al. PHARMACOLOGY & THERAPEUTICS
- HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
- (2021) Ilana Schlam et al. npj Breast Cancer
- Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs
- (2021) Elena Díaz-Rodríguez et al. Cancers
- Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study
- (2021) Zhi Peng et al. Cancer Communications
- ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer
- (2020) Mark Barok et al. CANCER LETTERS
- Epidermal growth factor receptor (EGFR) involvement in epithelial‐derived cancers and its current antibody‐based immunotherapies
- (2020) Max London et al. CELL BIOLOGY INTERNATIONAL
- A first in-human study of A166 in patients with locally advanced/metastatic solid tumors which are HER2-positive or HER2-amplified who did not respond or stopped responding to approved therapies.
- (2020) Yongheng Liu et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-human phase I study of ALT-P7, a HER2-targeting antibody-drug conjugate in patients with HER2-positive advanced breast cancer.
- (2020) Yeon Hee Park et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-human dose-escalation study of anti-EGFR ADC MRG003 in patients with relapsed/refractory solid tumors.
- (2020) Rui-hua Xu et al. JOURNAL OF CLINICAL ONCOLOGY
- Depatuxizumab mafodotin (ABT-414)-induced glioblastoma cell death requires EGFR overexpression, but not EGFRY1068 phosphorylation
- (2020) Caroline von Achenbach et al. MOLECULAR CANCER THERAPEUTICS
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
- (2020) Kohei Shitara et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells
- (2020) Wen-Qi Cai et al. Frontiers in Oncology
- Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase III ExteNET trial
- (2020) Arlene Chan et al. Clinical Breast Cancer
- Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials
- (2020) Seyed Samad Hosseini et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- EGFR targeting for cancer therapy: Pharmacology and immunoconjugates with drugs and nanoparticles
- (2020) Elias da Silva Santos et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
- (2019) Gabriel Rinnerthaler et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Recent Chemical Approaches for Site‐specific Conjugation of Native Antibodies: Technologies toward Next Generation Antibody‐Drug Conjugates
- (2019) Kei Yamada et al. CHEMBIOCHEM
- Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index
- (2019) Steven Coats et al. CLINICAL CANCER RESEARCH
- A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization
- (2019) Yuuri Hashimoto et al. CLINICAL CANCER RESEARCH
- Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
- (2019) Udai Banerji et al. LANCET ONCOLOGY
- U3-1402, a novel HER3-targeting antibody-drug conjugate, for the treatment of Colorectal Cancer
- (2019) Shigehiro Koganemaru et al. MOLECULAR CANCER THERAPEUTICS
- Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum‐pemetrexed for T790M mutation‐positive advanced non–small cell lung cancer
- (2019) Vassiliki A. Papadimitrakopoulou et al. CANCER
- INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFRamplified glioblastoma
- (2019) Martin van den Bent et al. NEURO-ONCOLOGY
- Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985)
- (2019) Zhuyu Xu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation
- (2019) Koji Haratani et al. JOURNAL OF CLINICAL INVESTIGATION
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- (2019) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients
- (2018) J Remon et al. ANNALS OF ONCOLOGY
- Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor
- (2018) Glenwood D. Goss et al. CANCER
- Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and EGFR-Activating Mutations
- (2018) Tony S. Mok et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
- (2018) Shang-Gin Wu et al. Molecular Cancer
- Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate
- (2018) Andrew C. Phillips et al. MOLECULAR CANCER THERAPEUTICS
- Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes
- (2018) Meghdad Abdollahpour-Alitappeh et al. JOURNAL OF CELLULAR PHYSIOLOGY
- An HER3-targeting antibody–drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC
- (2018) Kimio Yonesaka et al. ONCOGENE
- SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression
- (2017) Gulden Menderes et al. GYNECOLOGIC ONCOLOGY
- DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance
- (2017) Naoki Takegawa et al. INTERNATIONAL JOURNAL OF CANCER
- Dacomitinib versus gefitinib as first-line treatment for patients with EGFR -mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
- (2017) Yi-Long Wu et al. LANCET ONCOLOGY
- Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs
- (2017) Julian Andreev et al. MOLECULAR CANCER THERAPEUTICS
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
- (2017) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Development of New ADC Technology with Topoisomerase I Inhibitor
- (2017) Toshinori Agatsuma YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN
- An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer
- (2016) Hongwen Li et al. CANCER BIOLOGY & THERAPY
- A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
- (2016) John Y. Li et al. CANCER CELL
- Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity
- (2016) Yusuke Ogitani et al. CANCER SCIENCE
- Antibody–drug conjugates for cancer therapy
- (2016) Anish Thomas et al. LANCET ONCOLOGY
- Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
- (2016) Keunchil Park et al. LANCET ONCOLOGY
- Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
- (2016) Heather Donaghy mAbs
- ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope
- (2016) A. C. Phillips et al. MOLECULAR CANCER THERAPEUTICS
- Ikaros regulation of the BCL6/BACH2 axis and its clinical relevance in acute lymphoblastic leukemia
- (2016) Zheng Ge et al. Oncotarget
- Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness
- (2016) Arlene Chan Therapeutic Advances in Medical Oncology
- A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity
- (2015) Xuejing Yao et al. BREAST CANCER RESEARCH AND TREATMENT
- Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
- (2015) Nick Thatcher et al. LANCET ONCOLOGY
- Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
- (2015) Jean-Charles Soria et al. LANCET ONCOLOGY
- The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers
- (2015) M. M. C. van der Lee et al. MOLECULAR CANCER THERAPEUTICS
- Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody–Drug Conjugate SYD985
- (2015) Ronald C. Elgersma et al. MOLECULAR PHARMACEUTICS
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
- (2015) Sandra M. Swain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Internalization, Trafficking, Intracellular Processing and Actions of Antibody-Drug Conjugates
- (2015) Shi Xu PHARMACEUTICAL RESEARCH
- Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability
- (2015) Satish K. Singh et al. PHARMACEUTICAL RESEARCH
- Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy
- (2014) Ravi V. J. Chari et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Ado-trastuzumab Emtansine
- (2014) Patricia A. Corrigan et al. ANNALS OF PHARMACOTHERAPY
- Molecular Pathways: HER3 Targeted Therapy
- (2014) K. Gala et al. CLINICAL CANCER RESEARCH
- Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform
- (2014) W. Dokter et al. MOLECULAR CANCER THERAPEUTICS
- Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations
- (2014) P. Littlefield et al. Science Signaling
- First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung
- (2012) Ji-Youn Han et al. JOURNAL OF CLINICAL ONCOLOGY
- HER3 Overexpression and Survival in Solid Tumors: A Meta-analysis
- (2012) Alberto Ocana et al. JNCI-Journal of the National Cancer Institute
- Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion
- (2012) Erika Hamilton et al. Journal of Translational Medicine
- Panitumumab (Vectibix): Fig 1.
- (2011) J.J. Gemmete et al. AMERICAN JOURNAL OF NEURORADIOLOGY
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation
- (2010) Fumin Shi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- The HER4/4ICD Estrogen Receptor Coactivator and BH3-Only Protein Is an Effector of Tamoxifen-Induced Apoptosis
- (2008) A. Naresh et al. CANCER RESEARCH
- The epidermal growth factor receptor family: Biology driving targeted therapeutics
- (2008) M. J. Wieduwilt et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Severe Acneiform Eruption Induced by Cetuximab (Erbitux®)
- (2008) Jung Eun Lee et al. YONSEI MEDICAL JOURNAL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now